207 related articles for article (PubMed ID: 22895520)
1. Plasma Klotho is not related to kidney function and does not predict adverse outcome in patients with chronic kidney disease.
Seiler S; Wen M; Roth HJ; Fehrenz M; Flügge F; Herath E; Weihrauch A; Fliser D; Heine GH
Kidney Int; 2013 Jan; 83(1):121-8. PubMed ID: 22895520
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast Growth Factor 23 and α-Klotho Protein Are Associated with Adverse Clinical Outcomes in Non-Dialysis CKD Patients.
Manou E; Thodis E; Arsos G; Pasadakis P; Panagoutsos S; Papadopoulou D; Papagianni A
Kidney Blood Press Res; 2020; 45(6):900-915. PubMed ID: 33040068
[TBL] [Abstract][Full Text] [Related]
3. Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4.
Seiler S; Rogacev KS; Roth HJ; Shafein P; Emrich I; Neuhaus S; Floege J; Fliser D; Heine GH
Clin J Am Soc Nephrol; 2014 Jun; 9(6):1049-58. PubMed ID: 24677555
[TBL] [Abstract][Full Text] [Related]
4. Circulating α-klotho levels in CKD and relationship to progression.
Kim HR; Nam BY; Kim DW; Kang MW; Han JH; Lee MJ; Shin DH; Doh FM; Koo HM; Ko KI; Kim CH; Oh HJ; Yoo TH; Kang SW; Han DS; Han SH
Am J Kidney Dis; 2013 Jun; 61(6):899-909. PubMed ID: 23540260
[TBL] [Abstract][Full Text] [Related]
5. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.
Pavik I; Jaeger P; Ebner L; Wagner CA; Petzold K; Spichtig D; Poster D; Wüthrich RP; Russmann S; Serra AL
Nephrol Dial Transplant; 2013 Feb; 28(2):352-9. PubMed ID: 23129826
[TBL] [Abstract][Full Text] [Related]
6. Soluble α-klotho and its relation to kidney function and fibroblast growth factor-23.
Scholze A; Liu Y; Pedersen L; Xia S; Roth HJ; Hocher B; Rasmussen LM; Tepel M
J Clin Endocrinol Metab; 2014 May; 99(5):E855-61. PubMed ID: 24606097
[TBL] [Abstract][Full Text] [Related]
7. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
Milovanova LY; Milovanov YS; Kudryavtseva DV; Markina MM; Milovanova SY; Kozlovskaya LV; Lebedeva MV; Beketov VD; Moiseev SV; Mukhin NA; Fomin VV; Svistunov AA
Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189
[TBL] [Abstract][Full Text] [Related]
8. [Significance of the morphogenetic proteins FGF-23 and Klotho as predictors of prognosis of chronic kidney disease].
Milovanova LIu; Milovanov IuS; Kozlovskaia LV; Mukhin NA
Ter Arkh; 2014; 86(4):36-44. PubMed ID: 24864466
[TBL] [Abstract][Full Text] [Related]
9. [New markers of cardio-renal links in chronic kidney disease].
Milovanova LIu; Milovanov IuS; Kozlovskaia LV; Mukhin NA
Ter Arkh; 2013; 85(6):17-24. PubMed ID: 23866594
[TBL] [Abstract][Full Text] [Related]
10. Soluble Klotho is not independently associated with cardiovascular disease in a population of dialysis patients.
Buiten MS; de Bie MK; Bouma-de Krijger A; van Dam B; Dekker FW; Jukema JW; Rabelink TJ; Rotmans JI
BMC Nephrol; 2014 Dec; 15():197. PubMed ID: 25495997
[TBL] [Abstract][Full Text] [Related]
11. Plasma s-Klotho is related to kidney function and predicts adverse renal outcomes in patients with advanced chronic kidney disease.
Liu QF; Ye JM; Yu LX; He AL; Sun Q; He DW; Li SS
J Investig Med; 2018 Mar; 66(3):669-675. PubMed ID: 29061648
[TBL] [Abstract][Full Text] [Related]
12. Klotho and fibroblast growth factor 23 in cerebrospinal fluid in children.
Kunert SK; Hartmann H; Haffner D; Leifheit-Nestler M
J Bone Miner Metab; 2017 Mar; 35(2):215-226. PubMed ID: 27017221
[TBL] [Abstract][Full Text] [Related]
13. Plasma levels of fibroblast growth factor-23 are associated with muscle mass in haemodialysis patients.
Fukasawa H; Ishigaki S; Kinoshita-Katahashi N; Niwa H; Yasuda H; Kumagai H; Furuya R
Nephrology (Carlton); 2014 Dec; 19(12):784-90. PubMed ID: 25185859
[TBL] [Abstract][Full Text] [Related]
14. Serum klotho: relation to fibroblast growth factor-23 and other regulators of phosphate metabolism in children with chronic kidney disease.
Sawires HK; Essam RM; Morgan MF; Mahmoud RA
Nephron; 2015; 129(4):293-9. PubMed ID: 25766835
[TBL] [Abstract][Full Text] [Related]
15. The effect of nephrectomy on Klotho, FGF-23 and bone metabolism.
Kakareko K; Rydzewska-Rosolowska A; Brzosko S; Gozdzikiewicz-Lapinska J; Koc-Zorawska E; Samocik P; Kozlowski R; Mysliwiec M; Naumnik B; Hryszko T
Int Urol Nephrol; 2017 Apr; 49(4):681-688. PubMed ID: 28130714
[TBL] [Abstract][Full Text] [Related]
16. Reduced Levels of Anti-Ageing Hormone Klotho Predict Renal Function Decline in Type 2 Diabetes.
Fountoulakis N; Maltese G; Gnudi L; Karalliedde J
J Clin Endocrinol Metab; 2018 May; 103(5):2026-2032. PubMed ID: 29509906
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease.
Wan M; Smith C; Shah V; Gullet A; Wells D; Rees L; Shroff R
Nephrol Dial Transplant; 2013 Jan; 28(1):153-61. PubMed ID: 23180879
[TBL] [Abstract][Full Text] [Related]
18. New Insights into the Role of FGF-23 and Klotho in Cardiovascular Disease in Chronic Kidney Disease Patients.
Memmos E; Papagianni A
Curr Vasc Pharmacol; 2021; 19(1):55-62. PubMed ID: 32310050
[TBL] [Abstract][Full Text] [Related]
19. FGF23 and Klotho in chronic kidney disease.
Olauson H; Larsson TE
Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):397-404. PubMed ID: 23666415
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor 23/klotho axis in chronic kidney disease.
Nitta K; Nagano N; Tsuchiya K
Nephron Clin Pract; 2014; 128(1-2):1-10. PubMed ID: 25402964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
